OncoMedNewsشرکت نوآوران دارویی کیمیاhttp://kimia-pharma.co7/30/2026 12:40:55 AMenMevrometostat Plus Enzalutamide Confers a Survival Benefit for Patients With Hormone-Refractory mCRPChttps://www.kimia-pharma.co/en/mevrometostat-plus-enzalutamide-confers-a-survival-benefit-for-patients-with-hormone-refractory-mcrpc/ALK Tyrosine Kinase Inhibitors and Weight Gainhttps://www.kimia-pharma.co/en/alk-tyrosine-kinase-inhibitors-and-weight-gain/Neoadjuvant Modified Infusional Fluorouracil, Leucovorin, and Oxaliplatin With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancerhttps://www.kimia-pharma.co/en/neoadjuvant-modified-infusional-fluorouracil,-leucovorin,-and-oxaliplatin-with-or-without-radiation-versus-fluorouracil-plus-radiation-for-locally-advanced-rectal-cancer/Regorafenib delays disease progression in patients with soft tissue sarcomahttps://www.kimia-pharma.co/en/regorafenib-delays-disease-progression-in-patients-with-soft-tissue-sarcoma/CAPTIVATE Reveal Effectiveness, Durability of Combination Ibrutinib/Venetoclax for CLLhttps://www.kimia-pharma.co/en/captivate-reveal-effectiveness,-durability-of-combination-ibrutinib/venetoclax-for-cll/Checkpoint inhibition improves outcomes in high-risk, locally advanced cervical cancerhttps://www.kimia-pharma.co/en/checkpoint-inhibition-improves-outcomes-in-high-risk,-locally-advanced-cervical-cancer/Weekly dose of erlotinib shows decreased duodenal polyp burdenhttps://www.kimia-pharma.co/en/oncomednews/weekly-dose-of-erlotinib-shows-decreased-duodenal-polyp-burden/Combining Regorafenib Sensitivity and Functional Precision Medicine for Second-Line Treatment in Recurrent Glioblastomahttps://www.kimia-pharma.co/en/oncomednews/combining-regorafenib-sensitivity-and-functional-precision-medicine-for-second-line-treatment-in-recurrent-glioblastoma/